argenx SE (EBR:ARGX)
613.20
+10.00 (1.66%)
Sep 26, 2025, 5:36 PM CET
argenx SE Revenue
argenx SE had revenue of $967.19M USD in the quarter ending June 30, 2025, with 97.62% growth. This brings the company's revenue in the last twelve months to $3.12B, up 88.04% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.12B
Revenue Growth
+88.04%
P/S Ratio
14.12
Revenue / Employee
$1.95M
Employees
1,599
Market Cap
37.53B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UCB SA | 6.85B |
Financière de Tubize | 13.26K |
Fagron NV | 918.75M |
Ion Beam Applications | 585.76M |
Onward Medical | 2.72M |
Hyloris Pharmaceuticals | 8.90M |
Nyxoah | 4.93M |
Sequana Medical NV | 105.50K |
argenx SE News
- 10 days ago - Guggenheim Reiterates Buy Rating for ARGX with Target Price of $1070 | ARGX Stock News - GuruFocus
- 10 days ago - FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations - Business Wire
- 11 days ago - argenx SE - Special Call - Seeking Alpha
- 11 days ago - Argenx SE (ARGX) Discusses On R&D Spotlight | Pioneering MuSK Biology With ARGX-119 Conference Transcript - Seeking Alpha
- 12 days ago - argenx SE (ARGX) Special Call - Slideshow - Seeking Alpha
- 12 days ago - ARGX Quantitative Stock Analysis - Benjamin Graham - Nasdaq
- 16 days ago - argenx: Bullish On This R&D Focused Biotech Stock - Seeking Alpha
- 17 days ago - Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns - GuruFocus